Depo-Provera is an injectable contraceptive that is administered once every three months. For many years, it has been used by individuals seeking a long-acting birth control option that does not require daily attention. Its dosing schedule has made it a common choice in a variety of healthcare settings across the United States.
In recent years, however, scientific research has raised questions about potential health risks associated with extended use of Depo-Provera. A study published in The BMJ in March 2024 reported a higher incidence of meningiomas—a type of brain tumor—among women who used Depo-Provera for longer than one year. According to the study, prolonged use was associated with a 5.6-fold increased risk. These findings have contributed to a growing number of legal claims involving the drug’s manufacturer, Pfizer Inc.
Legal Actions and Allegations
As of May 2025, more than 130 lawsuits have been centralized into a federal multidistrict litigation (MDL). The lawsuits generally allege that Pfizer did not adequately warn patients and healthcare providers in the United States about the potential risk of meningiomas associated with Depo-Provera use. Plaintiffs point to the fact that product labeling in certain other countries, including members of the European Union and Canada, contains warnings regarding this risk, while U.S. labeling has not included similar language.
Among the cases cited is that of a woman from Utah who reportedly used Depo-Provera between 1996 and 2006 and was later diagnosed with a Grade II–III intracranial meningioma at the age of 31. Her claims, like others in the MDL, focus on alleged failures to provide sufficient safety information.
Understanding Meningiomas
Meningiomas develop in the membranes that surround the brain and spinal cord. Although many are considered noncancerous, they can still lead to serious medical complications. Symptoms may include ongoing headaches, changes in vision, seizures, or other neurological impairments. Treatment options vary based on the size and location of the tumor and may involve surgery, radiation therapy, or ongoing monitoring.
What This Means for You
Individuals who have used Depo-Provera and are experiencing persistent headaches, visual disturbances, or other unexplained neurological symptoms should consider seeking medical evaluation. Prompt diagnosis can play an important role in managing potential health issues.
Some individuals who have been diagnosed with meningiomas after using Depo-Provera are exploring their legal rights. Speaking with an attorney familiar with pharmaceutical litigation may help clarify whether a claim can be pursued, including potential recovery for medical costs, lost income, or other related damages.
